Now, it’s worth noting Stock Advisor’s total average return is 913 % — a market-crushing outperformance compared to 196% for ...
Pfizer (PFE) stock hold rating: 2026 patent cliff, falling Covid sales, GLP-1 obesity timeline, and M&A integration risks—read the outlook now.
New Chairman Joins Entera’s Board with Senior Global Leadership Experience from Pfizer, Wyeth and Other Leading Biopharma ...
C4 Therapeutics (NASDAQ:CCCC) executives outlined plans to advance their lead multiple myeloma program and expand the company ...
The vaccine maker’s shots involve the successful Covid vaccines’ RNA technology. Health Secretary Robert F. Kennedy Jr. has ...
The PROTAC market is experiencing rapid growth, driven by rising interest in targeted protein degradation as a next-generation therapeutic approach. Expanding oncology pipelines with drugs in clinical ...
New Haven-based Arvinas Inc. on Thursday named longtime executive Randy Teel as its new president and chief executive officer ...
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Detailed price information for Doximity Inc Cl A (DOCS-N) from The Globe and Mail including charting and trades.
Madrigal Pharma was the first drugmaker to bring a treatment for metabolic dysfunction-associated steatohepatitis (MASH) to ...
America’s drug safety agency declined to review a next-gen flu vaccine that uses the same tech as the coronavirus shots ...
Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results